How PSA Has Impacted the Use of ADT in Prostate Cancer

April 14, 2023

Video

Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.

Now Viewing

EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer

EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT

EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Recent Videos

Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.

Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

How PSA Has Impacted the Use of ADT in Prostate Cancer

EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer

EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT

EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Newsletter